Tata Sons

Tata Sons is the principal investment holding company and promoter of the Tata Group, a global conglomerate with a significant and expanding presence in the life sciences and healthcare sectors. The company's healthcare strategy is primarily executed through its subsidiary, Tata Medical and Diagnostics (Tata MD), which developed the world's first commercial CRISPR-based genomic test for COVID-19, known as FELUDA. Beyond diagnostics, Tata Sons oversees a diverse portfolio including Tata 1mg, a leading digital health and e-pharmacy platform, and Tata Consultancy Services (TCS), which provides extensive R&D and clinical trial services to the global pharmaceutical industry. The group also maintains a strong commitment to healthcare through the Tata Trusts, which operate one of the largest networks of cancer care hospitals in India. This integrated approach allows Tata Sons to leverage technology, manufacturing, and delivery systems to address complex healthcare challenges at scale.